Symbols

EU regulators back Novo Nordisk's (NVO.US) Wegovy for obesity-related heart disease

Friday, Sep 20, 2024 4:10 am ET1min read

Danish pharmaceutical company Novo Nordisk (NVO.US) said on Thursday that the European Medicines Agency (EMA) has supported the use of its blockbuster drug Wegovy to treat heart failure in patients with obesity, marking the second time the regulator has supported the use of the drug for an indication beyond weight loss and further strengthening Novo Nordisk's case for multiple health benefits.

AInvest Visual

Turning market noise into visual signal.

Latest Articles

Intel Courts Apple for Investment in High-Stakes Chip Revival

Sep.24 2025

Meta's High-Stakes Glasses Gambit: Hypernova Could Redefine Reality Labs' $70 Billion Bet

Sep.16 2025

Oracle's Stock Soars, Propelling Ellison Briefly Past Musk in "World's Richest" Race

Sep.10 2025

Apple's 2025 Event: A Slimmer iPhone and Subtle Shifts in a High-Stakes Market

Sep.09 2025

Here Are What You Need To Know About Apple's 'Awe Dropping' Event

Sep.09 2025

Comments

﻿

Add a public comment...

No comments yet

Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc's editorial and disclosure standards. Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content. AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.